Bunne C, Roohani Y, Rosen Y, et al. How to Build the Virtual Cell with Artificial Intelligence: Priorities and Opportunities. ArXiv. 2024.
Publications
Park RJ, Parikh M, Pappas L, et al. Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab. medRxiv : the preprint server for health sciences. 2024. doi:10.1101/2024.10.08.24315092
Halvorsen MW, de Schipper E, Bäckman J, et al. A burden of rare copy number variants in obsessive-compulsive disorder. Molecular psychiatry. 2024. doi:10.1038/s41380-024-02763-7
Zebardast N, Wiggs JL. How Genome-Wide Association Studies Transform Care for Patients at Risk of Glaucoma. Expert review of ophthalmology. 2024;19(4):243-246. doi:10.1080/17469899.2024.2365736
Hou D, Yu T. Innovative stroke intervention: Harnessing cerebral dopamine neurotrophic factor. Molecular therapy : the journal of the American Society of Gene Therapy. 2024. doi:10.1016/j.ymthe.2024.10.010
Bao R, Hutson A, Madabhushi A, et al. Ten challenges and opportunities in computational immuno-oncology. Journal for immunotherapy of cancer. 2024;12(10). doi:10.1136/jitc-2024-009721
Yu C, Natarajan P, Patel AP, et al. Polygenic risk, aspirin and primary prevention of coronary artery disease. European heart journal. Cardiovascular pharmacotherapy. 2024. doi:10.1093/ehjcvp/pvae085
Yu C, Natarajan P, Patel AP, et al. Polygenic risk, aspirin and primary prevention of coronary artery disease. European heart journal. Cardiovascular pharmacotherapy. 2024. doi:10.1093/ehjcvp/pvae085
Gonzalez-Ramos A, Berglind F, Kudláček J, et al. Chemogenetics with PSAM-GlyR decreases excitability and epileptiform activity in epileptic hippocampus. Gene therapy. 2024. doi:10.1038/s41434-024-00493-7
Gonzalez-Ramos A, Berglind F, Kudláček J, et al. Chemogenetics with PSAM-GlyR decreases excitability and epileptiform activity in epileptic hippocampus. Gene therapy. 2024. doi:10.1038/s41434-024-00493-7